Richard Skaife 🍄
@tokenrichard
Followers
2K
Following
4K
Media
1K
Statuses
12K
GP @ConsciousFundHQ CEO & Co Founder @LongrHQ Chair @MicroDoseHQ Advisor @Hive__Bio @HealingREIT @Psychedelic_Med. #PsyMed 🍄 #Longevity 🧪 #AI 🤖
Malta
Joined October 2008
The PMA recently turned FIVE years old! With all our activity putting together research bulletins & our monthly webinars for our members, the anniversary date in September already came and went. However, even if it is late we wanted to make sure to share this exciting milestone!
0
2
0
We cloned Gmail, except you're logged in as Epstein and can see his emails
1K
10K
132K
Cybin is pleased to announce a ~$175 million registered direct offering with prominent biotech investors. Learn more: https://t.co/s8m747QIou
4
7
24
We've completed the acquisition of Gilgamesh Pharmaceuticals' lead investigational asset. This expands our #psychiatry pipeline and underscores our commitment to pursue innovative approaches for #MentalHealth disorders. More: https://t.co/EwVez9Ptev
3
6
10
1/ It feels surreal to announce completion of the first human trial in the development of our neurotech platform for designing mental states, from the molecular level. Human experience is now programmable. A🧵on the sequel to psychedelics & the first new "emotion in a bottle."
171
416
3K
Great to see positive clinical results driving up stock prices. Not that long ago that a positive clinical read would do the opposite.
0
0
1
Positive news from team atai. Limbs crossed for a positive day on the markets. 📈
#News: atai Life Sciences $ATAI & @BeckleyPsytech announce results from the open-label Phase 2a study of BPL-003 in treatment-resistant depression. Read more: https://t.co/60uqpRWlh0
0
0
1
Chronic mTOR activation is like never taking your foot off the gas. It leads to cellular burnout, inflammation, and disease. Rapamycin introduces strategic braking - a weekly reset for your biology. 👉 https://t.co/pkTzsJd73Y
0
1
0
JUST IN: We’ve signed a definitive agreement to acquire @GilgameshRX lead investigational therapy. This agreement demonstrates our commitment to pursuing novel treatment approaches and transforming patient care in #psychiatry. Learn more: https://t.co/g9AJ4fzwKM
3
10
33
I was speaking to another ATAI shareholder last night, both of us expressing high levels of confidence. We continue to hold all of our positions from 2020 onwards in full.
I’ve gotten a lot of DMs recently asking why $ATAI share price has been so strong this year - both in absolute terms and relative to the biotech market and peers. Here’s why 👇
3
1
25
In 2023 we brought the longevity and PsyMed sector together for the first time @wonderlandconf . Now the clinical evidence starts to support what many of us have believed to be the case.
Psilocybin treatment extended lifespan and preserved telomeres in aged mice, suggesting potential as a geroprotective intervention. https://t.co/wGiOMwfdXi
#longevity #psilocybin #antiaging #biotech #geroscience #telomeres #lifespan
0
0
3
I’ve been a strong believer that PsyMed and Longevity are closely linked. Great to see this being studied more closely.
One good deed at a time. $ATAI focuses on mental health for now – over 1bn patients depend on us. But psychedelics may hold even broader potential, perhaps even in areas like life extension. We need gold-standard science to explore this. We’ll contribute. https://t.co/RVSi3fNESr
0
0
2
Is already ….
AI will become better at diagnosing complex health conditions than doctors.
0
0
1
A big day for Psy Med on the progress and investment front. Well done @C_Angermayer and all at team @atai_life
Today is another great day for $ATAI. We just announced outstanding Phase 2b data for BPL-003 (5-MeO-DMT). But that’s not all. Core shareholders, including myself, demonstrated our conviction in atai’s mission and potential by investing an additional $50 million alongside
0
0
7
Well done to all at team @CybinInc and @insidepharma - a huge vote of confidence for you and the sector.
Cybin is pleased to announce a financing of up to US$500M with High Trail Capital, providing funding to drive momentum across its Phase 3 CYB003 program and Phase 2 CYB004 program. “This financing represents a major inflection point for Cybin and supports our position as a
0
0
4
Your body already knows how it’s doing. It’s communicating in heartbeats, breath patterns, and recovery curves. We just give it a voice - and you, a plan. https://t.co/pkTzsJd73Y
0
2
1
A well-run Complete Blood Count (CBC) can flag risks ranging from anemia to early immune decline. It’s part of every Longevity Direct protocol. https://t.co/pkTzsJd73Y
0
1
0
Seeing lots of posts about 9-9-6 being the new norm. Very few people can do this for a prolonged period. You will burn out your best people. Adopt this at your peril.
0
0
0